Citations

Clear

6055 citation(s) found for "Wu, Peter".

Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomized trial
Than, Martin , Pickering, John W. , Buchan, Vanessa A, Florkowski, Christopher M , Mills, Nicholas L. , Hamill, Laura , Prystowsky, Jason, Harger, Simon, Reed, Mary, Bayless, Jared, Feberwee, Alexander, Attenburrow, Tamsin, Norman, Timothy, Welfare, Oliver, Heiden, Tamika L., Kavsak, Peter, Jaffe, Allan S. , Apple, Fred S. , Cullen, L, Aldous, Sally, Frampton, Christopher MA, Body, Richard, Lord, Sarah Jane, George, Peter Myles, Devlin, Gerard, Kavsak, Peter A. , Mills, Nicholas L , Than, Martin , Pickering, John W , Joyce, Laura R, Buchan, Vanessa, Florkowski, Christopher M , Hamill, Laura, Prystowsky, Jason, Harger, Simon, Reed, Mary, Bayless, Jared, Feberwee, Alexander, Attenburrow, Tamsin, Norman, Timothy, Welfare, Oliver, Heiden, Tamika, Kavsak, Peter , Jaffe, Allan S. , Apple, Fred S. , Peacock, William Frank , Cullen, Louise , Aldous, Sally, Richards, Arthur M , Lacey, Cameron, Troughton, Richard W , Frampton, Christopher, Body, Rick , Mueller, Christian , Lord, Sarah, George, Peter M, Devlin, Gerard

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351433 Get It

ABSTRACT BACKGROUND Point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) testing has the potential to expedite decision-making and reduce emergency department (ED) length of stay for patients presenting with possible myocardial infarction (MI) by ensuring that results are consistently available when looked for by clinicians. We assessed the real-life effectiveness and safety of implementing POC hs-cTn testing in the ED. METHODS We conducted a pragmatic, stepped-wedge cluster randomized trial. The control arm was usual care with an accelerated diagnostic pathway utilizing a single-sample rule-out step with a central laboratory hs-cTn assay. The intervention arm used the same pathway with a POC hs-cTnI. The primary effectiveness outcome was ED length of stay assessed using a generalized linear mixed model, and the safety outcome was 30-day MI or cardiac death. RESULTS Six sites participated with 59,980 ED presentations (44,747 individuals, 61±19 years, 49.5% female) from February 2023 to January 2025, in which 31,392 presentations were during the intervention arm. After adjustment for co-variates associated with length of stay, the intervention reduced length of stay by 13% (95% confidence intervals [CI], 9 to 16%. P<0.001), corresponding to a reduction of 47 minutes (95%CI, 33 to 61 minutes) from a mean length of stay in the control arm of 376 minutes. The 30-day MI or cardiac death rate was similar in the control and intervention arms (0.39% and 0.39% respectively, P=0.54). CONCLUSIONS Implementation of whole-blood hs-cTnI testing at the POC into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing. (Australia New Zealand Clinical Trials Registry ACTRN12619001189112) Clinical Perspective What is new? Point-of-care troponin assays with good precision have become available and received regulatory approval as high-sensitivity assays. A pragmatic stepped-wedge cluster randomized trial implementing the validated Siemens VTLi high-sensitivity point-of-care assay into 6 emergency departments investigating ∼60,000 patients, was conducted to ascertain if the rapid turnaround time reduced lengths of stay. Introduction of the VTLi high-sensitivity point-of-care assay into clinical pathways reduced emergency department lengths of stay by an average 13% (47 minutes) without compromising safety. What are the clinical implications? Early decision-making using a point-of-care high-sensitivity troponin assay within a structured clinical pathway was safe. Faster turnaround means troponin results are consistently available when clinicians first seek them. This can facilitate earlier decisions and reduce patient length of stay.
A Prediction Model for Risk of Death in Kidney Transplant Recipients
Debiais-Deschamps, Charlotte, Raynaud, Marc , Truchot, Agathe , Rudrapatna, Vivek A., Kers, Jesper, Vries, Aiko P. J. de, Gueguen, Juliette , Bouquegneau, Antoine , Legendre, Christophe, Jouven, Xavier, Mussell, Adam, McCauley, Brian, Emms, Sabrina, Mapchan, Shristi, Heilman, Raymond L. , Das, Devika , Kamar, Nassim, Anglicheau, Dany , Fowler, Kevin J., Naesens, Maarten, Lefaucheur, Carmen, Aubert, Olivier, Das, Devika , Debiais, Charlotte , Lombardi, Yannis , Divard, Gillian , Rudrapatna, Vivek A , Meziyerh, Soufian , Kers, Jesper , Helm, Danny van der , Vries, Aiko P. J. de , Bello, Arnaud Del , Loon, Elisabet Van , Legendre, Christophe , Jouven, Xavier , McCauley, Brian Daniel , Jadlowiec, Caroline C. , Kamar, Nassim , Fowler, Kevin John , Naesens, Maarten , Lefaucheur, Carmen , Aubert, Olivier , Reese, Peter P. , Loupy, Alexandre

Mayo Clinic

JAMA Network Open | April 23, 2026 | Volume: 9 | Issue: 4 | Pages: e267452

10.1001/jamanetworkopen.2026.7452 | PMID 42024384 Get It

Importance Accurate prediction of patient mortality after kidney transplant is an unmet need. Objective To develop and validate an integrative prediction model that predicts short- and long-term patient mortality for kidney recipients. Design, Setting, and Participants This international cohort study included patients who underwent transplants between 2004 and 2023 from 14 academic medical centers from Europe and the US. The derivation cohort consisted of 1566 consecutive adult kidney recipients in a deeply phenotyped cohort prospectively recruited in 1 French center between 2004 and 2014. External validation cohorts consisted of 10 951 kidney recipients from 7 centers in France, 3 centers in Europe, and 3 centers in North America who underwent kidney transplants between 2006 and 2023. Data were analyzed from January 2023 to June 2025. Main Outcome and Measures All-cause mortality was assessed, and 121 candidate prognostic factors, comprising demographics and clinical, biological, imaging, and immunological parameters, were collected. Results Among 12 517 kidney transplant recipients, including 1566 in the derivation cohort (mean [SD] age, 50.05 [14.31] years; 942 male [60.15%]) and 10 951 in validation cohorts (mean [SD] age, 53.32 [13.97] years; 6766 male [61.78%]), 2486 patients (19.9%) died after a median (IQR) follow-up of 5.08 (2.97-7.00) years. Fourteen prognostic factors (including clinical, biological, and imaging risk factors) were independently associated with patient death (eg, patient age: hazard ratio per 1-year increase in age, 1.07 [95% CI, 1.06-1.08]; P &amp;lt; .001) and were combined into a risk prediction model (mBox). The model exhibited accurate calibration and discrimination in the derivation cohort, with C statistics of 0.82 (95% CI, 0.77-0.87) and 0.80 (95% CI, 0.78-0.82) at 1 and 10 years, respectively, after the transplant. Abbreviated models were developed and validated to ensure model generalizability. Performance of abbreviated models was confirmed in external validation cohorts from France (C statistic, 0.76 [95% CI, 0.73-0.78]), Europe (C statistic, 0.74 [95% CI, 0.72-0.76]), the US (C statistic, 0.74 [95% CI, 0.70-0.78]), the Greater Paris University Hospital database (C statistic, 0.79 [95% CI, 0.77-0.81]), and the University of California at San Francisco database (C statistic, 0.70 [95% CI, 0.65-0.74]). The model was also validated in a series of subpopulations (eg, women vs men: C statistic, 0.81 [95% CI, 0.77-0.84] vs 0.79 [95% CI, 0.77-0.82]) and clinical scenarios (eg, before COVID-19 era: C statistic, 0.79 [95% CI, 0.77-0.81]) with good and stable performance. Conclusions and Relevance In this study, an accurate prediction model for mortality among kidney recipients, computable at the time of transplant, was developed and externally validated. Results suggest that this model may help stratify patient risk of death, allowing for improved medical decisions.
Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals
Ni, Zhanmo , Zhong, Jun , McKean, David, Antwi, Samuel O. , Bracci, Paige M., Du, Mengmeng, Gallinger, Steven, Genkinger, Jeanine, Haiman, Christopher A, Hassan, Manal, Huff, Chad , Kooperberg, Charles, Kastrinos, Fay , LeMarchand, Loic, Lee, WP, Oberg, Ann L. , Park, Margaret A. , Permuth, Jennifer B., Risch, Harvey A., Scheet, Paul , Schwartz, Ann, Shu, Xie, Wolpin, Brian M. , Albanes, Demetrius, Andreotti, Gabriella , Beane-Freeman, Laura, Berndt, Sonja I, Brennan, Paul, Buring, Julie E, Cabrera, Natalia, Campa, Daniele, Chanock, Stephen J, Chung, Charles C., Eliassen, A Heather, Gaziano, J. Michael, Giles, G G, Giovannucci, Edward L, Goggins, Michael, Goodman, Phyllis J. , Hicks, Belynda, Hutchinson, Amy , Jones , Katzke, Verena, Kogevinas, Manolis, Kurtz, Robert C. , Laheru, Daniel, Lee, I, Milne, Roger, Mucci, Lorelei, Patel, Alpa V, Peruchet, Laia, Peters, Ulrike, Porta, Miquel, Rabe, Kari G. , Real, Francisco X, Ricceri, Fulvio, Rothman, Nathaniel, Sesso, Howard D. , Setiawan, Veronica W, Debra, Silverman, Southey, M C, Stampfer, M I, Um, Caroline, Visvanathan, Kala, Wentzensen, Nicolas, Willett, Walter C, Kraft, Peter, Visvanathan, Kala , Zhong, Jun , Zheng, Wei , Canzian, Federico , Malats, Nuria , Duggal, Priya , Klein, Alison P , Chaffee, Kari G. , Antwi, Samuel O , Visvanathan, Kala , Vergara, Candelaria , McKean, David , Connelly, Katelyn E. , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng, Genkinger, Jeanine M. , Haiman, Christopher A. , Hung, Rayjean J. , Kooperberg, Charles , Lynch, Shannon M. , Moore, Steven C. , Permuth, Jennifer B. , Risch, Harvey A., Schwartz, Ann, Stolzenberg‐Solomon, Rachael Z. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Berndt, Sonja I. , Brennan, Paul, Buring, Julie E. , Cabrera-Castro, Natalia , Canzian, Federico , Chanock, Stephen Jacob , Chen, Yu , Gaziano, J. Michael , Giovannucci, Edward L. , Goggins, Michael , Hicks, Belynda , Katzke, Verena , Kogevinas, Manolis , Laheru, Daniel A. , Malats, Núria , Milne, Roger, Mucci, Lorelei A. , Neale, Rachel Ε. , Orlow, Irene , Peruchet‐Noray, Laia , Peters, Ulrike , Real, Francisco X. , Ricceri, Fulvio , Rothman, Nathaniel , Setiawan, Veronica Wendy , Silverman, Debra T. , Southey, Melissa C , Stampfer, Meir J. , Tobias, Geoffrey S. , Um, Caroline Y. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Duggal, Priya , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351329 | PMID 42078392 Get It

Abstract Pancreatic cancer disproportionately affects Black individuals in the United States, but they have limited representation in genetic studies of pancreatic ductal adenocarcinoma (PDAC). To address this gap, we performed admixture mapping and genome-wide association analysis (GWAS) in genetically inferred African ancestry individuals (1,030 cases and 889 controls). Admixture mapping identified three regions with a significantly higher proportion of African ancestry in cases compared to controls (5q33.3, 10p1, 22q12.3). GWAS identified a genome-wide significant association at 5p15.33 ( CLPTM1L , rs383009:T>C, T Allele Frequency=0.51, OR:1.45, P value=1.24×10 -8 ), a locus previously associated with PDAC. Known loci at 5p15.33, 7q32.3, 8q24.21 and 7q25.1 also replicated (P value <0.01). Multi-ancestral fine-mapping identified two potential causal SNPs (rs3830069 and rs2735940) at 5p15.33. Collectively these findings identified novel PDAC risk loci and expanded our understanding of this deadly cancer in underrepresented populations, emphasizing the multifactorial nature of PDAC risk including inherited genetic and non-genetic factors. Statement of Significance To understand how genetic variation contributes to PDAC risk in Black people in North American, we studied individuals of genetically-inferred African ancestry. We identified novel risk loci and differences in the contribution of known loci. This demonstrates that ancestry-informed genetic analyses improve our understanding of PDAC risk and enhances discovery.
Default mode network failure across the Alzheimer’s disease spectrum
Corriveau‐Lecavalier, Nick , Dicks, Ellen , Martin, Peter R. , Wiste, Heather J. , Gunter, Jeffrey L. , Kamykowski, Michael G. , Senjem, Matthew L, Schwarz, Christopher G. , Botha, Hugo , Graff‐Radford, Jonathan , Machulda, Mary M, Fields, Julie A. , Lowe, Val J, Petersen, Ronald C, Boeve, Brad , Knopman, David S. , Jack, Clifford R , Jones, David T , Schwarz, Christopher G , Botha, Hugo , Corriveau-Lecavalier, Nick , Senjem, Matthew L. , Machulda, Mary M. , Boeve, Bradley F. , Lowe, Val J. , Knopman, David S. , Petersen, Ronald C. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Brain | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag146 | PMID 42019008 Get It

Abstract Alzheimer’s disease (AD) emerges from multi-scale interactions between molecular pathology and disruptions in large-scale brain network dynamics. Understanding how these processes co-evolve and relate to disease stages is essential for advancing complex systems models of aging and AD, and for developing system-informed interventions. However, progress has been limited by a lack of large-scale longitudinal data. To address this, we examined the longitudinal relationship between subsystems of the default mode network (DMN) (posterior DMN, ventral DMN, anterior dorsal DMN) using task-free functional MRI (fMRI) and amyloid positron emission tomography (PET) imaging in a large longitudinal cohort spanning the clinico-biological spectrum of AD (n = 1,451; 2,763 time points) using mixed-effect models. We also assessed whether patterns of DMN connectivity predicted conversion to amyloid positivity, mild cognitive impairment (MCI), and dementia using Cox proportional hazards models. Our findings reveal a dynamic interplay between amyloid accumulation and connectivity within and between DMN subsystems, with both hyper- and hypoconnectivity emerging across DMN subsystems in association with increasing amyloid burden. Importantly, survival models showed that DMN connectivity patterns predicted conversion to critical stages of the disease, including not only conversion to MCI and dementia, but also conversion to amyloid positivity in otherwise clinically unimpaired individuals who were amyloid negative at baseline. These associations were independent of age, APOE4 status, sex, education, and in-scanner motion. These results support a model in which breakdowns in tightly regulated feedback loops governing DMN physiology represent a core systems-level pathophysiology of AD. Notably, this functional dyshomeostasis precedes detectable amyloidosis on imaging. Future studies should focus on the development of robust biomarkers of brain function that can be applied at the individual level, which could in turn help support the development of therapeutic approaches targeting system-level pathophysiology.
World Health Organization classification of tumours of the breast 6th edition 2026
Quinn, Cecily , Tan, Puay Hoon , Allison, Kimberly H. , Brogi, Edi , Lakhani, Sunil R. , Schnitt, Stuart J. , Fox, Stephen B. , Jaffer, Shabnam , Şahin, Ayşegül A. , Salgado, Roberto , Adjei, E, Helbich, Thomas H. , Sotiriou, C, Hodge, Jennelle C. , Khoury, Joseph D. , Puspanathan, Pavitratha, Giesen, Christine, Ruiz, Blanca Iciar Indave , Ellis, Ian, Lokuhetty, Dilani , Board, WCT Standing Editorial, Netto, George J. , Sahin, Aysegul , Sapino, Anna , Adjei, Ernest Kwasi , Geiersbach, Katherine , Helbich, Thomas H , Lambertini, Matteo , Sotiriou, Christos P. , Hodge, Jennelle C , Khoury, Joseph , Rekhi, Bharat , Ryska, Ales , Tse, Gary , Field, Andrew , Wijesinghe, Harshima , Puspanathan, Pavitratha , Giesen, Christine , Ruiz, Blanca Iciar Indave , Ellis, Ian , Lokuhetty, Dilani , Geiersbach, Katherine B. , Lambertini, Matteo , Field, Andrew , Ellis, Ian O. , board, WCT standing editorial

Mayo Clinic

Histopathology | April 21, 2026 | Volume: 89 | Issue: 2 | Pages: 199-218

10.1111/his.70149 | PMID 42011085 Get It

The 6th edition of the WHO Classification of Breast Tumours introduces both major and minor changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimens necessitating modifications to pathology reporting and tumour biomarker categorisation. This review summarises the main changes that strive towards a classification of global relevance. In invasive carcinoma, predictive factors increasingly inform modern breast cancer treatment. The 6th edition provides an update on HER2 reporting categories following the DESTINY‐Breast 04 and 06 trials. Terminologies used to classify invasive tumours are clarified, with the term ‘variant’ now reserved for molecular/genetic alterations. Invasive lobular carcinoma (ILC) with extracellular mucin is recognised as a new diagnostic entity with prognostic implications. The diagnosis of mucinous carcinoma (MC) is reserved for mucin secreting carcinomas with grade 1 or 2 morphology and a favourable biomarker profile. The diagnosis of malignant phyllodes tumours requires only four of the original five adverse histological criteria. Classification of neuroendocrine tumours (NETs) is revised, recognising that the unified model, promoted in the 5th edition, is difficult to apply to the breast. New approaches to the classification of adenomyoepithelioma are discussed but the 5th edition system is broadly retained. A new section on ‘Small Diagnostic Samples’ outlines the merits of non‐operative biopsy diagnosis, the B coding system and the importance of multidisciplinary review. Changes to diagnostic practice and the emerging role of artificial intelligence, with advantages and challenges, are discussed in a new section on ‘Digital Pathology’.
Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
Romich, Ellen , Ogdie, Alexis, Stephens‐Shields, Alisa, Merkel, Peter A., Assassi, Shervin , Bujor, Andreea M. , Castelino, Flavia V. , Chung, Lorinda, Evnin, Luke, Gordon, Jessica , Griffith, Melissa, Hant, Faye N. , Harding, Monica, Lakin, Kimberly S., Lebiedz‐Odrobina, Dorota J., Luo, Yiming, McMahan, Zsuzsanna H. , Molitor, Jerry, Moore, Duncan F. , RIchardson, Carrie, Shah, Amit N., Steen, Virginia, Volkmann, Elizabeth R. , Zahn, Carleigh , Sandorfi, Nora , Investigators, for the CONQUER, Chung, Leland W.K. , Bujor, Andreea , Castelino, Flavia V , Frech, Tracy M , Gordon, Jessica K , Hummers, Laura K , Khanna, Dinesh , Mayes, Maureen D , McMahan, Zsuzsanna H , Paik, Julie J , Skaug, Brian , Volkmann, Elizabeth R , Zahn, Carleigh , Chung, Lorinda , Assassi, Shervin , Ogdie, Alexis , Stephens‐Shields, Alisa J. , Merkel, Peter A. , Bernstein, Elana J. , Frech, Tracy , Khanna, Dinesh , Lakin, Kimberly S. , Lebiedz‐Odrobina, Dorota, Makol, Ashima , Mayes, Maureen D. , Molitor, Jerry A., Paik, Julie J. , Richardson, Carrie , Skaug, Brian , Shah, Ami A. , Shah, Ankoor, Steen, Virginia , VanBuren, John M.

Mayo Clinic

Arthritis Care & Research | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80069 | PMID 42007807 Get It

Objective This study aims to identify factors associated with patient global assessment (PtGA) and physician global assessment (PhGA) and discordance between them in systemic sclerosis (SSc). Methods Data from adults with early SSc (<5 years) from the Collaborative National Quality and Efficacy Registry were included. PtGA and PhGA (0–10 scale), clinical evaluations, and patient‐reported outcomes (PROs) were collected every six months. Multivariable mixed‐effects linear regression identified factors associated with PtGA and PhGA using (1) clinical variables and (2) clinical variables plus PROs. Relative weight analysis (RWA) determined the relative importance of each variable. Discordance (≥2 points between PtGA and PhGA) was assessed using multinomial mixed‐effects logistic regression. Results Among 956 patients (83% women, 33% limited disease), mean PtGA and PhGA at enrollment were 4.2 (SD 2.6) and 3.4 (SD 2.0), respectively ( P < 0.001). RWA of clinical variables identified modified Rodnan skin score (mRSS) and New York Heart Association (NYHA) functional class as most influential for both global assessments. After including PROs, PtGA was most influenced by measures of pain, skin symptoms, and physical function. Discordance occurred in 53% of patients (35% PtGA worse, 18% PhGA worse). Worse PtGA was associated with higher overall pain and discomfort. Worse PhGA was associated with higher mRSS, worse NYHA class, higher pain interference, and lower diffusing capacity of the lung. Conclusion Discordance between PtGA and PhGA occurs commonly, highlighting the need for comprehensive symptom management and measurement of disease burden in this complex disease. In SSc, differences in PtGA and PhGA reflect dissimilar weighting of data elements.
Return to sport after meniscectomy, meniscal repair, and meniscal allograft transplantation for meniscal lesions in athletes: A systematic review and meta‐analysis
Bensa, Alessandro , Piano, Andrea , Fumagalli, Giacomo Arthur, Krych, Aaron John, Verdonk, Peter, Krych, Aaron J. , Verdonk, Peter , Filardo, Giuseppe

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ksa.70404 | PMID 42003662 Get It

Abstract Purpose The aim of this systematic review and meta‐analysis was to quantify and compare the evidence on the results obtained with the surgical treatments for meniscal lesions in athletes. Methods A literature search was conducted on PubMed, Cochrane and Web of Science in August 2025 according to the PRISMA guidelines. Inclusion criteria were clinical studies (randomised controlled trials [RCTs], non‐randomised comparative studies and case series), ≥6 patients, in the English language, on the surgical treatment of meniscal lesions in athletes. A meta‐analysis was conducted on the rate of patients returning to sport, the time to return to sport, and the rate of patients returning to the pre‐injury level of sport. Patient‐reported outcome measures, adverse events, failures and reoperation rates, as well as risk of bias and quality of evidence, were also documented. The risk of bias was assessed using the Cochrane RoB 2.0 tool, the Cochrane ROBINS‐I tool, and the JBI Critical appraisal checklist. The quality of evidence was assessed using a modified Coleman score and the GRADE tool. Result The mean time to return to sport was 2.1 months for meniscectomy, 5.8 months for meniscal repair, and 8.9 months for meniscal allograft transplantation (MAT). Statistically significant differences were observed between meniscectomy and repair and between meniscectomy and MAT (both p < 0.001). Meniscectomy showed a return to sport rate of 98.2%, meniscal repair of 96.9%, and MAT of 94.2%, while return to the same pre‐injury level of sport was reported as 84.4% for meniscectomy, 81.3% for meniscal repair, and 77.4% for MAT, with no statistically significant differences between groups. The mean modified Coleman Methodology Score for the included studies was 66.6 ± 7.0. Conclusion Meniscectomy, meniscal repair, and MAT are all able to provide high rates of return to sport in athletes. In the investigated treatment cohorts, meniscectomy presented the shortest pooled time to return to sport, followed by meniscal repair and MAT. Importantly, all treatments offered good rates of return to the same level of athletic performance. The treatment choice should be guided by an individualised, multidisciplinary approach aimed at providing a patient‐tailored treatment strategy to optimise both athletic recovery and joint preservation. Level of Evidence Level I.
Patient's Age Impact on Stroke Risk and Intracranial Aneurysm Occlusion: SCENT Flow Diverter Study—A Nonrandomized Clinical Trial on Large and Giant Aneurysms
Wakhloo, Ajay K. , Jenkins, Paul, Meyers, Philip M. , Coon, A , Kan, Peter T., Puri, Ajit S., Vries, Joost de, Lanzino, Giuseppe, Bain, Mark D., Ebersole, Koji , Welch, B, Dog⫧an, Aclan , Jabbour, Pascal M., Mocco, J., Siddiqui, Adnan H., Turk, Aquilla S., Taussky, Philipp, Hanel, Ricardo A., Investigators, for the SHaRe and IPHCC, Siddiqui, Adnan H. , Siddiqui, Adnan H , Coon, Alexander Lewis , Kan, Peter , Puri, Ajit S., Vries, Joost de , Lanzino, Giuseppe , Welch, Babu G. , Jabbour, Pascal , Turk, Aquilla S , Taussky, Philipp , Hanel, Ricardo A.

Mayo Clinic

Neurosurgery Practice | April 17, 2026 | Volume: 7 | Issue: 2 | Pages: No page available

10.1227/neuprac.0000000000000222 | PMID 42007246 Get It

BACKGROUND AND OBJECTIVES: The prospective single-arm nonrandomized SCENT (Surpass Intracranial Aneurysm Embolization System Pivotal) trial on flow diverter treatment of large and giant intracranial aneurysms (IA) was analyzed for patients' age and IA characteristics affecting stroke and occlusion rates over 5 years (Trial registration NCT01716117). METHODS: Impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as 65 years and younger vs older than 65. Kaplan–Meier estimates of time to both endpoints, stratified by age, were created. Univariate predictors of time-to-stroke were analyzed using univariable proportional hazards regression models. Limited bivariable modeling was also attempted. RESULTS: Of 180 patients with large or giant IA enrolled, 119 were 65 years and younger, whereas 61 were older than 65 years. The 3-year risk of stroke for the older than 65 years group (19.7%) was more than double that of the 65 years and younger group (9.2%), P = .047. No new strokes were reported between 3 and 5 years. Four patients (2.2%) experienced aneurysm rupture within the first week post-treatment, 3 being 65 years and younger and the fourth older than 65 (>.99). Complete IA occlusion within age strata at 1 year was: older than 65 60% (33/55), 65 years and younger 79.1% (87/110), P = .009, 3 years: older than 65 67.6% (25/37), 65 years and younger 82.5% (66/80), P = .071, and 5 years: older than 65 85.7% (18/21), 65 years and younger 91.8% (56/61), P = .417. CONCLUSION: Age older than 65 was associated with an increased risk of stroke and predictive of incomplete healing and increased time to healing.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
The Efficacy of Bracing in Nonoperative Care of Medial Femoral Condyle Osteochondritis Dissecans: A Study From the Research in Osteochondritis Dissecans of the Knee (ROCK) Study Group
Group, The ROCK, Nissen, Carl W. , Albright, Jay C. , Anderson, Christian N. , Busch, Michael T., Carey, James L. , Carlson, Cathy , Carsen, Sasha , Crepeau, Allison, Edmonds, Eric W. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John B. , Godin, Jonathan , Ganley, Theodore J. , Grimm, Nathan L. , Heyworth, Benton E. , Po, James Hui Hoi, Kocher, Mininder S., Koehler, Ryan, Latz, Kevin, Loveland, Dustin M., Lyon, Roger M., Meenen, Norbert M., Milewski, Matthew D., Myer, Gregory D., Nelson, Bradley J., Nepple, Jeffrey, Nguyen, Jie C. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Riley, Pat, Saluan, Paul, Shea, Kevin G., Tompkins, Marc , Wall, Eric J. , Willimon, S. Clifton , Wright, Rick W. , Shea, Kevin G. , Edmonds, Eric W , Ellis, Henry B , Fabricant, Peter D , Ganley, Theodore J , Green, Daniel W , Heyworth, Benton E , Krych, Aaron J , Pace, J Lee , Pennock, Andrew T , Perkins, Crystal A , Tompkins, Marc A , Nissen, Carl , Busch, Michael T., Carlson, Cathy, Chambers, Henry G. , Godin, Jonathan, Hui, James Hoi Po, Kocher, Mininder Singh , Koehler, Ryan J. , Krych, Aaron J. , Lyon, Roger, Meenen, N. M., Milewski, Matthew D. , Myer, Gregory D. , Nelson, Bradley J. , Nepple, Jeffrey J. , Weiss, Jennifer M., Wilson, Philip L. , Kostyun, Regina O.

Mayo Clinic

The American Journal of Sports Medicine | April 15, 2026 | Volume: 54 | Issue: 6 | Pages: 1415-1422

10.1177/03635465261429407 | PMID 41981903 Get It

Background: Stable osteochondritis dissecans (OCD) lesions are primarily treated nonoperatively. Nonoperative treatment includes several recommendations, including the use of an unloader brace. However, little is known about the clinical effectiveness of unloader bracing and its influence on OCD healing, return to sports, and patient-reported outcomes (PROs). The purpose of this investigation was to evaluate the impact of unloader bracing on patients with stable medial femoral condyle (MFC) OCD lesions treated nonoperatively. Purpose: To investigate the influence of valgus unloader bracing on the success of treating stable MFC OCD with nonoperative treatment strategies. Study Design: Cohort study; Level of evidence, 2. Methods: The authors used a prospective cohort of patients receiving nonoperative care for stable MFC knee OCD lesions. The primary variable of interest was the efficacy of bracing. The primary outcomes were transition from nonoperative care to surgical intervention, return-to-play (RTP) clearance, and PROs. Bivariate testing was used to determine if there were differences between groups. Chi-square testing was used to determine if there were differences in rates of transition to surgery by group. The timing of the transition by each group was assessed using a Wilcoxon rank-sum test, given the nonparametric nature of the data. Kaplan-Meier survival analysis was used to calculate time at risk, incidence rate, and survival times for each group. Results: A total of 185 knees (bracing group: 123 [66.5%] knees; no-bracing group: 62 [33.5%] knees) were analyzed. Overall, 142 (76.8%) knees were successfully treated nonoperatively. Transition to surgery occurred in 43 (23.2%) knees. There were no differences in transition to surgery by groups, with no differences seen by group. Of the knees that did not transition to surgical care, 65 (71.4%) in the bracing group and 38 (74.5%) in the no-bracing group received RTP clearance ( P = .693). PRO scores were similar between the 2 groups at the time of RTP clearance. Conclusion: The inclusion of an unloader brace in the nonoperative treatment for stable MFC OCD lesions did not decrease the likelihood of patients undergoing surgical intervention or improve their PRO scores at the time of RTP clearance. Registration: NCT02771496 (ClinicalTrials.gov identifier).